Powered by

Genkyotex reports positive interim results from GKT831 trial

Nov 06, 2018 - Marketline Newswire

Genkyotex has reported positive interim efficacy results from the Phase II trial of GKT831 for the treatment of primary biliary cholangitis (PBC).

The trial met both its primary and secondary interim efficacy endpoints after six weeks of treatment.The trial's primary efficacy endpoint is a change in gamma glutamyl transferase (GGT) at week 24, while secondary endpoints include additional markers of liver and bile duct injury, markers of inflammation, and non-invasive markers of liver fi...